BioSyent Inc. (CVE:RX – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday. The company traded as high as C$18.40 and last traded at C$17.99, with a volume of 9,231 shares. The stock had previously closed at C$18.10.
BioSyent Stock Down 0.6%
The company has a market capitalization of C$202.06 million, a PE ratio of 21.07 and a beta of 1.08. The company has a debt-to-equity ratio of 6.85, a current ratio of 2.07 and a quick ratio of 6.91. The company has a 50-day moving average of C$16.80 and a two-hundred day moving average of C$15.23.
Insider Transactions at BioSyent
In related news, Director Seyed Ahmad Ashrafi sold 2,900 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of C$16.55, for a total value of C$47,995.00. Following the completion of the sale, the director directly owned 21,461 shares of the company’s stock, valued at approximately C$355,179.55. This represents a 11.90% decrease in their position. Over the last ninety days, insiders have sold 7,251 shares of company stock valued at $118,207. Corporate insiders own 33.65% of the company’s stock.
About BioSyent
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Featured Articles
- Five stocks we like better than BioSyent
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
